DK1503788T3 - Behandling af alpha-galactosidase A-deficiens - Google Patents

Behandling af alpha-galactosidase A-deficiens

Info

Publication number
DK1503788T3
DK1503788T3 DK03726489.2T DK03726489T DK1503788T3 DK 1503788 T3 DK1503788 T3 DK 1503788T3 DK 03726489 T DK03726489 T DK 03726489T DK 1503788 T3 DK1503788 T3 DK 1503788T3
Authority
DK
Denmark
Prior art keywords
deficiency
galactosidase
alpha
treatment
methods
Prior art date
Application number
DK03726489.2T
Other languages
English (en)
Inventor
Douglas A Treco
Kenneth Loveday
Marianne Borowski
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Application granted granted Critical
Publication of DK1503788T3 publication Critical patent/DK1503788T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
DK03726489.2T 2002-04-25 2003-04-25 Behandling af alpha-galactosidase A-deficiens DK1503788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37558402P 2002-04-25 2002-04-25
PCT/US2003/013063 WO2003090695A2 (en) 2002-04-25 2003-04-25 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY

Publications (1)

Publication Number Publication Date
DK1503788T3 true DK1503788T3 (da) 2011-10-17

Family

ID=29270665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03726489.2T DK1503788T3 (da) 2002-04-25 2003-04-25 Behandling af alpha-galactosidase A-deficiens

Country Status (13)

Country Link
US (6) US20040071686A1 (da)
EP (2) EP1503788B1 (da)
JP (5) JP5570677B2 (da)
AT (1) ATE514430T1 (da)
AU (2) AU2003228722B2 (da)
BR (2) BR122017016940B8 (da)
CA (1) CA2483270C (da)
DK (1) DK1503788T3 (da)
ES (1) ES2367257T3 (da)
HK (1) HK1073608A1 (da)
IL (4) IL164757A0 (da)
NZ (1) NZ536361A (da)
WO (1) WO2003090695A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1503788B1 (en) * 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006029233A2 (en) 2004-09-07 2006-03-16 Zymequest, Inc. Apparatus for prolonging survival of platelets
DE602005026043D1 (de) * 2004-10-15 2011-03-03 Velico Medical Inc Zusammensetzungen und verfahren für die verlängerung der überlebensdauer von blutplättchen
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
EP2121005A1 (en) * 2006-12-21 2009-11-25 Academisch Ziekenhuis bij de Universiteit van Amsterdam Treatment of fabry disease
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
WO2009032171A1 (en) * 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US20120230974A1 (en) * 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
IL291556B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Methods and compositions for administration of arylsulfatase A to the central nervous system
RU2660348C2 (ru) 2010-06-25 2018-07-05 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки в цнс идуронат-2-сульфатазы
EP2588130B1 (en) * 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
NZ702800A (en) 2010-06-25 2017-03-31 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
AU2012204526B2 (en) 2011-01-03 2016-05-19 California Institute Of Technology High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
DK2665814T3 (da) 2011-01-20 2017-09-11 Protalix Ltd Nukleinsyrekonstruktion til ekspression af alpha-galactosidase i planter og planteceller
ES2675511T3 (es) * 2011-07-14 2018-07-11 Grifols, S.A. Análisis rápido y preciso de la sialilación de proteínas
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
US11130980B2 (en) * 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
KR102438885B1 (ko) * 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6996676B2 (ja) * 2016-03-30 2022-02-04 国立研究開発法人農業・食品産業技術総合研究機構 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
CN117959455A (zh) * 2017-01-05 2024-05-03 波塔力克斯有限公司 植物重组人类α-半乳糖苷酶制备治疗法布里病的药品的用途
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
DE20168827T1 (de) 2017-06-30 2021-01-21 Gtx Medical B.V. System zur neuromodulierung
JP7252211B2 (ja) * 2017-09-08 2023-04-04 ザ ヌムール ファウンデーション リソソーム蓄積症を治療するための薬剤、デバイス、および血液循環システム、ならびにリソソーム蓄積症を治療するための方法
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
KR20210106537A (ko) 2018-12-20 2021-08-30 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
EP3827871A1 (en) 2019-11-27 2021-06-02 ONWARD Medical B.V. Neuromodulation system
CN116096898A (zh) * 2020-02-28 2023-05-09 科德克希思公司 人类α半乳糖苷酶变体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658567A (en) * 1899-10-14 1900-09-25 Elmer G Howard Threshing-machine attachment.
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
EP0159604B1 (en) * 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en) * 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
WO1990011353A1 (en) 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
KR0159107B1 (ko) * 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
ES2104610T3 (es) * 1989-09-05 1997-10-16 Biotech Australia Pty Ltd Proceso para la preparacion de pai-2.
JP2688854B2 (ja) 1989-10-27 1997-12-10 株式会社ホーネンコーポレーション 糖転移活性の強いα―ガラクトシダーゼの製造法
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
WO1992006187A1 (en) 1990-09-28 1992-04-16 The Upjohn Company Transgenic animals with alzheimer's amyloid precursor gene
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
EP0568647B1 (en) 1991-01-21 1996-09-11 Genzyme Corporation Production of enzymatically active glucocerebrosidase from recombinant cells
JP4215273B2 (ja) 1991-04-25 2009-01-28 ブラウン ユニヴァーシティ リサーチ ファンデーション 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993008292A1 (en) 1991-10-16 1993-04-29 Agracetus, Inc. Particle-mediated transformation of animal somatic cells
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
JPH09508783A (ja) * 1993-09-23 1997-09-09 ニユー・イングランド・バイオレイブス・インコーポレイテツド 新規なグリコシダーゼの単離及び組成物
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
EP1538202B1 (en) 1996-09-13 2014-01-22 Shire Human Genetic Therapies, Inc. Production of human alpha-galactosidase A
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
HUP0101355A3 (en) 1998-05-07 2003-08-28 Transkaryotic Therapies Inc Ca Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
EP1075514A1 (en) 1998-05-07 2001-02-14 Transkaryotic Therapies, Inc. Modifying the expression of the fsh beta gene by homologous recombination
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
EP1503788B1 (en) * 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency

Also Published As

Publication number Publication date
EP1503788A4 (en) 2008-09-03
IL257056B (en) 2021-03-25
AU2003228722A1 (en) 2003-11-10
US20060177433A1 (en) 2006-08-10
BR122017016940B8 (pt) 2021-07-27
US20170216411A1 (en) 2017-08-03
JP2014196343A (ja) 2014-10-16
US20160184409A1 (en) 2016-06-30
AU2009217430B2 (en) 2012-10-18
JP2018016630A (ja) 2018-02-01
IL220043A0 (en) 2012-06-28
JP5570677B2 (ja) 2014-08-13
NZ536361A (en) 2008-05-30
JP5981151B2 (ja) 2016-08-31
JP2016180003A (ja) 2016-10-13
BRPI0309665B8 (pt) 2021-05-25
US20190255156A1 (en) 2019-08-22
IL280818A (en) 2021-04-29
EP1503788B1 (en) 2011-06-29
JP2012140431A (ja) 2012-07-26
JP6492139B2 (ja) 2019-03-27
AU2003228722B2 (en) 2009-06-25
JP6225224B2 (ja) 2017-11-01
IL257056A (en) 2018-06-28
CA2483270A1 (en) 2003-11-06
US20110002908A1 (en) 2011-01-06
US11116823B2 (en) 2021-09-14
ES2367257T3 (es) 2011-10-31
JP2005538941A (ja) 2005-12-22
US20040071686A1 (en) 2004-04-15
AU2009217430A1 (en) 2009-10-15
WO2003090695A3 (en) 2004-05-06
IL164757A0 (en) 2005-12-18
US10245304B2 (en) 2019-04-02
HK1073608A1 (en) 2005-10-14
IL220043B (en) 2018-02-28
EP1503788A2 (en) 2005-02-09
US9523113B2 (en) 2016-12-20
BR0309665A (pt) 2005-08-16
ATE514430T1 (de) 2011-07-15
BR122017016940B1 (pt) 2020-11-10
IL280818B (en) 2021-12-01
US9267166B2 (en) 2016-02-23
CA2483270C (en) 2015-03-31
BRPI0309665B1 (pt) 2019-07-16
WO2003090695A2 (en) 2003-11-06
US7833742B2 (en) 2010-11-16
EP2361631A1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
PL374865A1 (en) Treatment of tnf alpha related disorders
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60328797D1 (de) Blutbehandlungsgerät
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
DE60327877D1 (de) Blutverarbeitungssysteme mit blutverarbeitungskammer und versorgungsleitung
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20053903D0 (no) Nukleotidlipidesterderivater.
ITMI20030897A1 (it) Procedimento e apparecchiatura per frazionare sangue.
DE60220220D1 (de) Blutbehandlungssystem
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
BR0302037B1 (pt) método e aparelho de tratamento de costura.
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
NO20022747L (no) Behandlingsstol
ZA200103745B (en) Therapeutic light source and method.
NO20011900L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav
ZA200103743B (en) Therapeutic light source and method.
ITMI20022446A1 (it) Sostanze e metodi di trattamento anti-androgenetico
BR8303683Y1 (pt) disposiÇço em aparelho para tratamento, particularmente da regiço da face e pescoÇo